AU782657C - Vaccination against canine herpesvirus infection and vaccines - Google Patents

Vaccination against canine herpesvirus infection and vaccines

Info

Publication number
AU782657C
AU782657C AU33831/01A AU3383101A AU782657C AU 782657 C AU782657 C AU 782657C AU 33831/01 A AU33831/01 A AU 33831/01A AU 3383101 A AU3383101 A AU 3383101A AU 782657 C AU782657 C AU 782657C
Authority
AU
Australia
Prior art keywords
chv
herpesvirus infection
vaccines
against canine
canine herpesvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU33831/01A
Other versions
AU782657B2 (en
AU3383101A (en
Inventor
Herve Poulet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial SAS filed Critical Merial SAS
Publication of AU3383101A publication Critical patent/AU3383101A/en
Publication of AU782657B2 publication Critical patent/AU782657B2/en
Application granted granted Critical
Publication of AU782657C publication Critical patent/AU782657C/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention concerns the use of a CHV antigen for preparing a vaccine against canine herpesvirus infection, to be administered to the pregnant bitch as close as possible to birth, preferably during the last third of pregnancy, and producing a high anti-CHV antibody rate in the pregnant bitch at the time of birth, inducing protection in the pups by antibody transfer during suckling. The invention also concerns an inactivated anti-CHV or subunit vaccine, useful for vaccinating pregnant females to protect pups by antibody transfer.
AU33831/01A 2000-01-21 2001-01-19 Vaccination against canine herpesvirus infection and vaccines Expired AU782657C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0000797A FR2804026B1 (en) 2000-01-21 2000-01-21 VACCINATION AGAINST HERPESVIROSE CANINE AND VACCINES
FR0000797 2000-01-21
PCT/FR2001/000189 WO2001052887A2 (en) 2000-01-21 2001-01-19 Vaccination against canine herpesvirus infection and vaccines

Publications (3)

Publication Number Publication Date
AU3383101A AU3383101A (en) 2001-07-31
AU782657B2 AU782657B2 (en) 2005-08-18
AU782657C true AU782657C (en) 2006-07-13

Family

ID=8846182

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33831/01A Expired AU782657C (en) 2000-01-21 2001-01-19 Vaccination against canine herpesvirus infection and vaccines

Country Status (13)

Country Link
EP (1) EP1248648B1 (en)
JP (1) JP2003520249A (en)
AT (1) ATE540693T1 (en)
AU (1) AU782657C (en)
BR (2) BRPI0107771B1 (en)
CA (1) CA2397861C (en)
FR (1) FR2804026B1 (en)
HU (1) HU228703B1 (en)
MX (1) MXPA02007115A (en)
NZ (1) NZ520242A (en)
PL (1) PL209070B1 (en)
WO (1) WO2001052887A2 (en)
ZA (1) ZA200205830B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512368A (en) * 2002-12-19 2006-04-13 アクゾ・ノベル・エヌ・ベー Trivalent vaccine that transmits maternal antibodies through milk
EP1843787B1 (en) * 2005-01-28 2011-11-02 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804197A (en) * 1996-02-15 1998-09-08 Heska Corporation Recombinant canine herpesviruses
WO1999044633A1 (en) * 1998-03-03 1999-09-10 Merial Live recombined vaccines injected with adjuvant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
AU532186B2 (en) 1978-07-21 1983-09-22 Merck & Co., Inc. Herpes virus vaccine
NZ226811A (en) * 1987-11-03 1991-06-25 Syntex Inc Adjuvant emulsion comprising a glycopeptide and non-toxic tetra-polyol or pop-poe block copolymer wherein oily particle size is less than 800am
JPH11106351A (en) * 1997-10-02 1999-04-20 Chemo Sero Therapeut Res Inst Oil adjuvant vaccine and its production
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
FR2776928B1 (en) * 1998-04-03 2000-06-23 Merial Sas ADJUVATED DNA VACCINES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804197A (en) * 1996-02-15 1998-09-08 Heska Corporation Recombinant canine herpesviruses
WO1999044633A1 (en) * 1998-03-03 1999-09-10 Merial Live recombined vaccines injected with adjuvant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZENTRABLATT FUR VETERINARMEDIZIN REIHE B (1980) 4, 257-87 *

Also Published As

Publication number Publication date
HU228703B1 (en) 2013-05-28
FR2804026A1 (en) 2001-07-27
PL209070B1 (en) 2011-07-29
ZA200205830B (en) 2003-09-29
AU782657B2 (en) 2005-08-18
PL356556A1 (en) 2004-06-28
CA2397861A1 (en) 2001-07-26
FR2804026B1 (en) 2004-06-11
AU3383101A (en) 2001-07-31
HUP0203831A2 (en) 2003-03-28
BR0107771A (en) 2002-11-12
EP1248648B1 (en) 2012-01-11
CA2397861C (en) 2017-04-04
NZ520242A (en) 2004-06-25
EP1248648A2 (en) 2002-10-16
JP2003520249A (en) 2003-07-02
ATE540693T1 (en) 2012-01-15
MXPA02007115A (en) 2003-01-28
BRPI0107771B1 (en) 2017-06-13
WO2001052887A2 (en) 2001-07-26
HUP0203831A3 (en) 2004-07-28
WO2001052887A3 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
Morein et al. Current status and potential application of ISCOMs in veterinary medicine
Hu et al. Immunostimulating complexes (ISCOMs) for nasal vaccination
Nobiron et al. Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
NO20015073D0 (en) vaccinations
HK1121382A1 (en) Adjuvant compositions for enhancing immune responses to polynucleotide- based vaccines
MXPA01007760A (en) Immunological adjuvant compound.
DE60012042D1 (en) ENTEPNEUMOVIRUS AND APPROPRIATE VACCINE
WO2007106404A2 (en) Vaccine for viruses that cause persistent or latent infections
EP1471936A4 (en) Hiv vaccine and method of use
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
DE60136928D1 (en) USE OF PLANT OIL BODY IN VACCINATE ADMINISTRATION SYSTEMS
AU782657C (en) Vaccination against canine herpesvirus infection and vaccines
SE9903534D0 (en) Vaccine
Toussaint et al. Prime-boost strategies combining DNA and inactivated vaccines confer high immunity and protection in cattle against bovine herpesvirus-1
Petzhold et al. Neutralizing antibodies to bovine herpesviruses types 1 (BHV-1) and 5 (BHV-5) induced by an experimental, oil-adjuvanted, BHV-1 vaccine
TN2014000393A1 (en) Modified marek's disease virus, and vaccines made therefrom
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor
WO2004043286A3 (en) Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
Dias et al. Study of the immune response induced by different adjuvants
UA67249A (en) Strain paramixovirus-3 bovis "m-87" for the preparation of vaccine and diagnostic antigen
Babiuk Novel approaches for developing vaccines
MD1855F1 (en) Method of poultry immunization against viral infections (variants)
Schijns et al. Rationales for including adjuvants in vaccines

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired